Marked Underestimation of Serum 25-hydroxyvitamin D Concentrations by The Abbot Architect Chemiluminescent Microparticle Immunoassay in Patients Receiving Vitamin D2 Supplementation
- 14 October 2021
- journal article
- letter
- Published by Elsevier BV in Endocrine Practice
- Vol. 28 (1), 122-123
- https://doi.org/10.1016/j.eprac.2021.10.002
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Vitamin D for skeletal and non-skeletal health: What we should knowJournal of Clinical Orthopaedics and Trauma, 2019
- Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological ConditionsFrontiers in Endocrinology, 2019
- The When, What & How of Measuring Vitamin D Metabolism in Clinical MedicineNutrients, 2018
- Hydroxyvitamin D assays: An historical perspective from DEQASThe Journal of Steroid Biochemistry and Molecular Biology, 2018
- Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose?cclm, 2017
- Performance evaluation of two immunoassays for 25-hydroxyvitamin DJournal of Clinical Biochemistry and Nutrition, 2016
- Performance evaluation of four 25-hydroxyvitamin D assays to measure 25-hydroxyvitamin D2Clinical Biochemistry, 2015
- Fortification of Foods with Vitamin D in IndiaNutrients, 2014
- Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice GuidelineJournal of Clinical Endocrinology & Metabolism, 2011
- Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assaysAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2006